Orphan Synergy Europe - Pharma Aktie
| 5,76EUR | 0,15EUR | 2,67% |
WKN DE: A14QXP / ISIN: FR0012127173
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 51 | 61 | 67 | 55 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,20 | 0,43 | 0,27 | 0,04 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 40 | 44 | 37 | 30 | 70 |
| Summe Anlagevermögen | 57 | 57 | 54 | 51 | 54 |
| Summe Aktiva | 97 | 102 | 92 | 82 | 124 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 36 | 54 | 59 | 59 | 60 |
| Summe Eigenkapital | 61 | 48 | 33 | 23 | 64 |
| Summe Passiva | 97 | 102 | 92 | 82 | 124 |
Adresse
| 22, Boulevard Benoni Goullin, 44000 Nantes | |
| Telefon | +33 (2) 28-29-10-10 |
| Internet | http://www.ose-immuno.com |
Management
|
Anne-Laure Autret-Cornet
Director, Chief Financial & Administrative Officer |
|
Aurore Morello
Director-Research & R&D Programs |
|
Brigitte Dreno
Independent Director |
|
Cécile Nguyen Cluzel
Independent Director |
|
Didier Hoch
Chairman |
|
Eric Jean Marie Leire
Independent Director |
|
Fiona Olivier
Chief Corporate Affairs Officer |
|
Jean Jacques Mention
Chief Business Officer |
|
Jean-Pascal Conduzorgues
Chief Manufacturing Officer |
|
Laurence de Schoulepnikoff
Chief Operating & Business Officer |
|
Linda Lebon
Chief Regulatory Officer |
|
Marc Dechamps
Independent Director |
|
Markus Goebel
Independent Director |
|
Martine Ortin George
Independent Director |
|
Maryvonne Hiance
Vice Chairman & Public Affairs Director |
|
Nicolas Poirier
Chief Executive Officer & Director |
|
Silvia Comis
Head-Clinical Development |
|
Sonya Montgomery
Chief Development Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.